June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
αB-Crystallin interaction with Alzheimer’s Disease Amyloid-β potentiates Aβ-Mediated Neurotoxicity
Author Affiliations & Notes
  • Juliet A Moncaster
    Psychiatry, Boston University, Boston, MA
  • Thor Stein
    Boston University, Boston, MA
  • Rajendra Gangalum
    Jules Stein, UCLA, Los Angeles, CA
  • Srikant Sarangi
    Boston University, Boston, MA
  • Olga Minaeva
    Boston University, Boston, MA
  • Suraj P Bhat
    Jules Stein, UCLA, Los Angeles, CA
  • John Voss
    UC Davies, Sacramento, CA
  • Carmela Abraham
    Boston University, Boston, MA
  • Patric K Stanton
    New York Medical College, Valhalla, NY
  • Lee E Goldstein
    Psychiatry, Boston University, Boston, MA
  • Footnotes
    Commercial Relationships Juliet Moncaster, None; Thor Stein, None; Rajendra Gangalum, None; Srikant Sarangi, None; Olga Minaeva, None; Suraj Bhat, None; John Voss, None; Carmela Abraham, None; Patric Stanton, None; Lee Goldstein, Cognoptix (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5585. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Juliet A Moncaster, Thor Stein, Rajendra Gangalum, Srikant Sarangi, Olga Minaeva, Suraj P Bhat, John Voss, Carmela Abraham, Patric K Stanton, Lee E Goldstein; αB-Crystallin interaction with Alzheimer’s Disease Amyloid-β potentiates Aβ-Mediated Neurotoxicity. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5585. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Alzheimer’s disease neuritic plaque is composed of amyloid-β (Aβ) and also contains low molecular weight chaperones including αB-crystallin. We investigated the hypothesis that these ubiquitous molecular chaperones might potentiate pathogenic protein aggregation and neurotixicity by interacting with Aβ.

Methods: Immunogold electron microscopy, SDS-page and immunoblotting, spectral reflectance imaging biosensor, electrophysiology, cell and organotypic slice culture.

Results: Immunohistochemical analysis of human Alzheimer’s disease brain revealed co-localization of human Aβ and human αB-crystallin in neuritic plaque. Immunohistochemistry and immunoblotting analysis demonstrated that αB-crystalllin is expressed and secreted from astrocytes through an exosomal pathway. Immunogold electron microscopic experiments showed that human αB-crystalllin arrested human Aβ peptide fibrillogenesis and sequestered this amyloidogenic peptide into soluble complexes. αB-Crystallin dose-dependently potentiated Aβ cytotoxicity in SH-SY5Y human neuroblastoma cells.

Conclusions: Our data show that αB-crystallin is expressed and secreted by astrocytes, binds to Aβ and enhances its toxicity to both synaptic function and neuronal survival, probably by increasing the concentration of low molecular weight soluble Aβ complexes. These properties of αB-crystallin suggest an antagonistic pleiotropy that may be critical to the pathogenesis of Alzheimer’s disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×